Search
Ascentage Pharma Group International
AAPGAdd to Watchlist
18.070USD
+0.110+0.61%
Market hours （ET）Quotes delayed by 15 min
6.75BMarket Cap
--P/E TTM
More Details of Ascentage Pharma Group International Company
Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.
Ascentage Pharma Group International Info
Ticker SymbolAAPG
Company nameAscentage Pharma Group International
IPO dateOct 28, 2019
CEOYang (Dajun)
Number of employees- -
Security typeDepository Receipt
Fiscal year-end- -
Address68 Xinqing Road, Suzhou Industrial Park
CitySUZHOU
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryChina
Postal code- -
Phone
Websitehttps://www.ascentage.cn/
Ticker SymbolAAPG
IPO dateOct 28, 2019
CEOYang (Dajun)
Company Executives of Ascentage Pharma Group International
Name
Name/Position
Position
Shareholding
Change
Dr. Dajun Yang, M.D., Ph.D.
Dr. Dajun Yang, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Shaomeng Wang, Ph.D.
Dr. Shaomeng Wang, Ph.D.
Non-Executive Director, Co-Founder
Non-Executive Director, Co-Founder
--
--
Dr. Dazhong (Simon) Lu, Ph.D.
Dr. Dazhong (Simon) Lu, Ph.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Wei Ren
Mr. Wei Ren
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. Yifan Zhai, M.D., Ph.D.
Dr. Yifan Zhai, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Raymond Jeffrey (Jeff) Kmetz
Mr. Raymond Jeffrey (Jeff) Kmetz
Chief Business Officer
Chief Business Officer
--
--
Mr. Thomas Joseph (Tom) Knapp, J.D.
Mr. Thomas Joseph (Tom) Knapp, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Ms. Marina S. Bozilenko
Ms. Marina S. Bozilenko
Independent Non-Executive Director
Independent Non-Executive Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Dajun Yang, M.D., Ph.D.
Dr. Dajun Yang, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Shaomeng Wang, Ph.D.
Dr. Shaomeng Wang, Ph.D.
Non-Executive Director, Co-Founder
Non-Executive Director, Co-Founder
--
--
Dr. Dazhong (Simon) Lu, Ph.D.
Dr. Dazhong (Simon) Lu, Ph.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Wei Ren
Mr. Wei Ren
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
FAQs
Who are the top five shareholders of Ascentage Pharma Group International?
The top five shareholders of Ascentage Pharma Group International are: Dr. Dajun Yang, M.D., Ph.D.
How many institutions hold shares of Ascentage Pharma Group International (AAPG)?
As of 2026Q1, 25 institutions hold shares of Ascentage Pharma Group International, with a combined market value of approximately 65.84K, accounting for 0.07% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -220958.00.